Accordingly, it should be noticed that in our study, T2D patients starting basal insulin therapy had a mean age of 68 years and a mean disease duration of 9 years, with an overall preserved renal function, whereas those starting fast-acting insulin overall showed the same mean age, with a longer diabetes duration (12 vs 9 years) and a slightly worse renal function (41% vs 36% of patients with eGFR < 60 ml/min/1.73m2). This evidence concerns the gene INS and diabetes mellitus.